Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address


  Print      Mail a friend       Annual reports

Wednesday 07 September, 2011


ZYTIGA approved in the EU

RNS Number : 7862N
07 September 2011

BTG plc: ZYTIGA™ (abiraterone acetate) approved in the EU


London, UK, 7 September 2011: BTG plc (LSE: BGC), the specialist healthcare company, is pleased to note the announcement by Janssen-Cilag International NV that the European Commission has approved ZYTIGA™ (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of men with metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel.


BTG will receive an undisclosed milestone payment following the EU approval together with a royalty on worldwide sales of abiraterone acetate.


The full text of the announcement by Janssen-Cilag International NV follows.




First once-daily, oral treatment inhibits androgen production at all sources


Beerse, Belgium, September 7, 2011 /PRNewswire/ - Janssen-Cilag International NV announced today that, after an accelerated regulatory review process by the European Medicines Agency (EMA) and following a positive CHMP opinion on the 22 July 2011, the European Commission has approved the marketing authorisation for ZYTIGA® (abiraterone acetate), a novel, once-daily, oral, androgen biosynthesis inhibitor. Abiraterone acetate is approved, in combination with prednisone or prednisolone, for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.1


"The European Commission approval of abiraterone acetate gives new hope to men who are suffering from this late stage of prostate cancer with very few treatment options left," said Professor Karim Fizazi, Department of Cancer Medicine, Institut Gustave Roussy, France, who was an investigator in the abiraterone acetate pivotal Phase 3 study. "The efficacy, safety and ease of use of abiraterone acetate, a medicine that can be taken at home, will address an important unmet medical need for many patients, helping them to live longer with a better quality of life and less pain."


Abiraterone acetate is an androgen biosynthesis inhibitor that inhibits the CYP17 enzyme complex which is required for the production of androgens.1 Androgens (e.g. testosterone) are hormones that promote the development and maintenance of male sex characteristics.2 However, in prostate cancer, androgens can fuel the tumour's growth.3 Androgen production primarily occurs in the testes and adrenal glands but, in men with prostate cancer, the tumour tissue is an additional source of androgens.1 Abiraterone acetate is the first oral treatment for metastatic castration-resistant prostate cancer that inhibits androgen production at all three sources.1


Results of the pivotal Phase 3, randomised, placebo-controlled, multicentre study showed that at a pre-specified interim analysis, after a follow-up of 12.8 months, treatment with abiraterone acetate in combination with prednisone or prednisolone resulted in a 35.4 percent reduction in the risk of death [hazard ratio (HR) = 0.65; 95 percent CI: 0.54, 0.77; p<0.001] and an improvement of 3.9 months in median overall survival (14.8 months vs. 10.9 months) compared to placebo plus prednisone or prednisolone.4 In an updated analysis (with follow-up period of 20.2 months), results were consistent with those from the interim analysis with a 4.6 month improvement in median overall survival between the two arms (15.8 months vs. 11.2 months [HR = 0.74]) in favour of abiraterone acetate. The effect of abiraterone acetate and prednisone on overall survival was consistent across all subgroups.4


In patients who reported significant pain from their disease (a baseline pain score of 4 or more using the Brief Pain Inventory-Short Form [BPI-SF] scale of 0 to 10) and with at least one post-baseline pain score, the percentage experiencing pain relief (at least a 30% reduction from baseline in the BPI-SF worst pain intensity score over 24 hours without any increase in analgesic usage score observed at two consecutive evaluations four weeks apart) was higher in the abiraterone acetate group than in the placebo group (44% versus 27%, p=0.002).4

A lower proportion of patients receiving abiraterone acetate had skeletal related events compared with those given placebo (18% vs 28% at six months, 30% vs 40% at 12 months and 35% vs 40% at 18 months).1 A skeletal related event was defined as a pathological fracture (a broken bone caused by disease weakening the bone), spinal cord compression, palliative radiation to bone (used to lessen bone pain), or surgery to bone.4


"In patients who have exhausted standard treatment options, including chemotherapy, abiraterone acetate offers a novel, well tolerated option for treating this devastating disease," explained Professor Johann S. de Bono, MD, FRCP, MSc, PhD, The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, and one of the co-lead investigators for the Phase 3 clinical study. "In Europe, prostate cancer is the third most common cause of cancer deaths so it is essential that new treatments options like abiraterone acetate are developed."


Overall, compliance with abiraterone acetate treatment was high, and side effects were easily manageable and reversible, despite the advanced age and level of frailty of the study population.4 The most common adverse reactions seen with abiraterone acetate are peripheral oedema, hypokalaemia, hypertension and urinary tract infection.1


Abiraterone acetate should be taken once a day on an empty stomach, at least two hours after eating, and no food should be eaten for at least one hour after taking the tablets.1


About pivotal phase 3 study -COU-AA-301



Abiraterone acetate with prednisone was evaluated in a Phase 3, randomised, placebo-controlled, multi-centre clinical study in patients who had received prior chemotherapy containing docetaxel (N = 1,195). Patients were randomised 2:1 to receive abiraterone acetate 1,000 milligrams (mg) daily plus prednisone or prednisolone 5 mg twice daily or placebo in combination with prednisone or prednisolone 5 mg twice daily (control arm). This randomised, double-blind placebo-controlled Phase 3 study was conducted in 147 centres in 13 countries.4


About metastatic castration-resistant prostate cancer

Metastatic castration-resistant prostate cancer, or mCRPC, occurs when cancer has metastasised (spread) beyond the prostate and disease progresses despite serum testosterone below castrate levels.5


The prostate is a gland in men that produces part of the seminal fluid and is located around the urethra (under the bladder).6 In some cases, cancer of the prostate can grow slowly compared with other cancers. However, depending on factors including characteristics specific to the patient and the tumour, prostate cancer also can grow very quickly and spread widely.7


In 2008, an estimated 370,000 new cases of prostate cancer were diagnosed in Europe, and nearly 90,000 men died from the disease.8


About Janssen

Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to addressing and solving the most important unmet medical needs of our time, including oncology (e.g. multiple myeloma and prostate cancer), immunology (e.g. psoriasis), neuroscience (e.g. schizophrenia, dementia and pain), infectious disease (e.g. HIV/AIDS, hepatitis C and tuberculosis), and cardiovascular and metabolic diseases (e.g. diabetes).


Driven by our commitment to patients, we develop sustainable, integrated healthcare solutions by working side-by-side with healthcare stakeholders, based on partnerships of trust and transparency.

More information can be found at



1.   ZYTIGA® summary of product characteristics 2011.

2.   National Cancer Institute. Dictionary of Cancer Terms - Androgen. Available at: [Last accessed August 2011].

3.   American Cancer Society. Cancer Facts & Figures 2010. Atlanta: American Cancer Society; 2010

4.   de Bono JS et al. Abiraterone and Increased Survival in Metastatic Prostate Cancer. N Engl J Med 2011; 364(21): 1995-2005.

5.   Hotte SJ, Saad F. Current management of castrate-resistant prostate cancer. Curr Oncol. 2010 September; 17(Supplement 2): S72-S79.

6.   An Introduction to Prostate Cancer. Prostate Cancer Foundation. 2009. Available at:{705B3273-F2EF-4EF6-A653-E15C5D8BB6B1}/IntroProstateCancer.pdf. Accessed November 2009.

7.   Mayo Clinic. "Prostate Cancer." [Last accessed August 2011].

8. [last accessed August 2011]



About BTG

BTG is an international specialist healthcare company that is developing and commercialising products targeting critical care, cancer and other disorders. The company is seeking to acquire new products to develop and market to specialist physicians, and is building a sustainable business financed by revenues from sales of its own marketed products and from royalties and milestone payments on partnered products.


For further information contact:


BTG                                                                                                                        Financial Dynamics                                                                                                                                                                                                                                                                                                                                                                                                                                                     Financial Dynamics

Andy Burrows, Director of Investor Relations                                                Ben Atwell

+44 (0)20 7575 1741; Mobile: +44 (0)7990 530605                                    +44 (0)20 7831 3113


Rolf Soderstrom, Chief Financial Officer
+44 (0)20 7575 0000 

This information is provided by RNS
The company news service from the London Stock Exchange

a d v e r t i s e m e n t